Study 44 of 46Orforglipron (LY-3502970) literatureJAMATop journal2026
Orforglipron for Obstructive Sleep Apnea: Research Summary.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus14
Preclinical · this one
9
Observational
1
Open-label
14
Randomised
8
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
ASafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%reviewAOrforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).JAMA · 2026 · Mean AHI change was -17.8 for orforglipron vs -4.5 for placebo in trial 1, difference -13.2 [95% CI, -17.7 to -8.7]; P < 0.001 at 52 weeks.HumanAEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.HumanBPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes, obesity & metabolism · 2025 · n=800 · 84.2% preferred Treatment A vs 15.8% for Treatment B.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.Human